文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

COAPT上市后研究:5000例继发性二尖瓣反流行TEER

Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

COAPT-PAS是一项前瞻性单臂观察性研究,纳入2019-2020年间美国406个中心连续5000例接受MitraClip治疗的继发性二尖瓣反流患者,报告1年结局。患者合并症更多、心衰更重、指南导向药物治疗使用少于COAPT或MITRA-FR随机试验,但MitraClip植入率97.7%,1年二尖瓣反流≤2+比例达90.7%,生活质量显著改善,临床事件率与随机试验MitraClip组相似或更低,且低于单纯药物治疗组。

要点

  • 真实世界5000例继发性二尖瓣反流患者行MitraClip,1年二尖瓣反流≤2+达90.7%。
  • 1年心衰住院率:COAPT-PAS全队列18.9%,COAPT相似组19.7%(COAPT随机试验24.9%)。
  • MITRA-FR相似组1年心衰住院率28.7%,低于MITRA-FR随机试验的47.4%。

核心结论

  • 大型当代真实世界研究证实MitraClip系统在继发性二尖瓣反流患者中安全有效,包括符合COAPT或MITRA-FR随机试验入选/排除标准者及被随机试验排除的患者。

研究设计与样本

  • COAPT-PAS为前瞻性单臂观察性研究,纳入2019至2020年美国406个参与TVT注册中心的连续5000例接受MitraClip治疗的继发性二尖瓣反流患者。
  • 报告全队列及符合随机试验入选/排除标准的COAPT相似组(n=991)和MITRA-FR相似组(n=917)的1年结局。

主要发现

  • COAPT-PAS患者较COAPT或MITRA-FR随机试验患者合并症更多、心衰和功能受限更重、指南导向药物治疗更少。
  • 全队列、COAPT相似组和MITRA-FR相似组的MitraClip植入率97.7%,1年二尖瓣反流≤2+比例分别为90.7%、89.7%和86.6%。
  • 1年生活质量改善(堪萨斯城心肌病问卷评分)分别为+29、+27和+33。
  • 1年心衰住院率:COAPT-PAS全队列18.9%,COAPT相似组19.7%(COAPT随机试验24.9%),MITRA-FR相似组28.7%(MITRA-FR随机试验47.4%)。
  • 手术时间更快,临床事件率与随机试验MitraClip组相似或更低,且低于随机试验单纯指南导向药物治疗组。

临床怎么用

  • 在真实世界继发性二尖瓣反流患者中,包括合并症多、心衰重及随机试验未纳入者,MitraClip治疗仍可安全有效降低二尖瓣反流并改善生活质量。
  • COAPT相似组和MITRA-FR相似组均显示1年心衰住院率低于对应随机试验的单纯药物治疗组,支持对合适患者行TEER。

局限性

  • 单臂观察性研究,缺乏同期对照组,与随机试验比较为非随机对照。
  • 仅报告1年结局,长期耐久性未明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Real-world applicability of the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) randomized controlled trial (RCT) has been debated because of careful patient selection and the contrasting results of the MITRA-FR (Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients with Severe Secondary Mitral Regurgitation) RCT. OBJECTIVES: The COAPT-PAS (COAPT Post-Approval Study) was initiated to assess the safety and effectiveness of the MitraClip in patients with secondary mitral regurgitation (SMR). METHODS: COAPT-PAS is a prospective, single-arm, observational study of 5,000 consecutive patients with SMR treated with the MitraClip at 406 U.S. centers participating in the TVT (Transcatheter Valve Therapy) registry from 2019 to 2020. The 1-year outcomes from the COAPT-PAS full cohort and the COAPT-like and MITRA-FR-like subgroups who met RCT inclusion/exclusion criteria are reported. RESULTS: Patients in the COAPT-PAS had more comorbidities, more severe HF and functional limitations, and less guideline-directed medical therapy than those in the COAPT or MITRA-FR RCTs. Patients in the COAPT-PAS full cohort and the COAPT-like (n = 991) and MITRA-FR-like (n = 917) subgroups achieved a 97.7% MitraClip implant rate, a similar and durable reduction of mitral regurgitation to ≤2+ at 1 year (90.7%, 89.7%, and 86.6%, respectively), a large improvement in quality of life at 1 year (Kansas City Cardiomyopathy Questionnaire +29 COAPT-PAS, +27 COAPT-like, and +33 MITRA-FR-like), faster procedure times, similar or lower clinical event rates compared with the RCTs' MitraClip arms, and lower clinical event rates than the RCTs' guideline-directed medical therapy only arms. One-year heart failure hospitalizations was 18.9% in COAPT-PAS, 19.7% in COAPT-like compared with 24.9% in COAPT-RCT, and 28.7% in COAPT-PAS-MITRA-FR-like compared with 47.4% in MITRA-FR-RCT. CONCLUSIONS: This large, contemporary, real-world study reinforces the safety and effectiveness of the MitraClip System in patients with SMR, including those who met the COAPT or MITRA-FR RCT inclusion/exclusion criteria and patients excluded from the RCTs.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Goel K, Lindenfeld J, Makkar R, et al. Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study. J Am Coll Cardiol. 2023. PMID: 37730284. doi:10.1016/j.jacc.2023.07.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。